Sun, Feb 1, 2015, 1:22 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • agateviewresident agateviewresident Dec 8, 2012 8:13 AM Flag

    Wall Street doesn't like the word "unprecedented"...

    True. However, with the "unprecidented" response it is almost a moot point. ...Almost. Although, the clinical trials will reach capacity quickly, the results will be immediate, the news from all the various clinical trials will travel fast, off-label use will accelerate even quicker.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The results of this study were first presented in Feb 2011 at ASCO GU, since then they have been updated two or three times. It does not diminish the significance of the results, but it does explain the muted reaction as this is not new data. The next significant data release I see is the survival analysis fromt the MTC EXAM trial in late 2013 or early 2014. This may well occur some time proximate to the release of topline results for Comet 2. There will be other presentations of various phase 2 results, but the market tends to discount uncontrolled trial data.

1.87-0.10(-5.08%)Jan 30 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.